Glenmark Pharmaceuticals Ltd.

₹1442.9

Glenmark Pharmaceuticals Ltd.

₹1442.9

₹1442.9

25.5 (1.8%) - 14 May 2025 04:31 PM

About Company

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Market Cap. ₹ 40,719 Cr.
52 Week - High/Low ₹ 1,831/985
P/E Ratio 6.42
P/B Ratio 1.70
Enterprise Value ₹ 42,148 Cr.
ROE % 25.3
RSI Value 55.15
EMA 50 1422.37
EMA 200 1422.9
Market Cap. ₹ 40,719 Cr.
52 Week - High/Low ₹ 1,831/985
P/E Ratio
P/B Ratio 4.97
Enterprise Value ₹ 36,973 Cr.
ROE % -21.18
RSI Value 55.15
EMA 50 1422.37
EMA 200 1422.9

Growth

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.